98 related articles for article (PubMed ID: 31871020)
1. Naringenin Enhances the Antitumor Effect of Therapeutic Vaccines by Promoting Antigen Cross-Presentation.
Wang L; Zeng W; Wang L; Wang Z; Yin X; Qin Y; Zhang F; Zhang C; Liang W
J Immunol; 2020 Feb; 204(3):622-631. PubMed ID: 31871020
[TBL] [Abstract][Full Text] [Related]
2. Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.
Zhang Y; Chen G; Liu Z; Tian S; Zhang J; Carey CD; Murphy KM; Storkus WJ; Falo LD; You Z
J Immunol; 2015 Jun; 194(12):5937-47. PubMed ID: 25972487
[TBL] [Abstract][Full Text] [Related]
3. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
4. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
5. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
[TBL] [Abstract][Full Text] [Related]
6. GM-CSF increases cross-presentation and CD103 expression by mouse CD8⁺ spleen dendritic cells.
Zhan Y; Carrington EM; van Nieuwenhuijze A; Bedoui S; Seah S; Xu Y; Wang N; Mintern JD; Villadangos JA; Wicks IP; Lew AM
Eur J Immunol; 2011 Sep; 41(9):2585-95. PubMed ID: 21660938
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
Song MY; Park SH; Nam HJ; Choi DH; Sung YC
J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
[TBL] [Abstract][Full Text] [Related]
8. A Brucella spp. Protease Inhibitor Limits Antigen Lysosomal Proteolysis, Increases Cross-Presentation, and Enhances CD8+ T Cell Responses.
Coria LM; Ibañez AE; Tkach M; Sabbione F; Bruno L; Carabajal MV; Berguer PM; Barrionuevo P; Schillaci R; Trevani AS; Giambartolomei GH; Pasquevich KA; Cassataro J
J Immunol; 2016 May; 196(10):4014-29. PubMed ID: 27084100
[TBL] [Abstract][Full Text] [Related]
9. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments.
Kang TH; Lee JH; Noh KH; Han HD; Shin BC; Choi EY; Peng S; Hung CF; Wu TC; Kim TW
Int J Cancer; 2007 Apr; 120(8):1696-703. PubMed ID: 17230516
[TBL] [Abstract][Full Text] [Related]
10. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K; Soares L; Engleman EG; Merad M
J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
[TBL] [Abstract][Full Text] [Related]
11. CD103
Lu L; Tanaka Y; Ishii N; Sasano T; Sugawara S
Eur J Immunol; 2017 Feb; 47(2):305-313. PubMed ID: 27861804
[TBL] [Abstract][Full Text] [Related]
12. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
13. Liver-resident CD103+ dendritic cells prime antiviral CD8+ T cells in situ.
Krueger PD; Kim TS; Sung SS; Braciale TJ; Hahn YS
J Immunol; 2015 Apr; 194(7):3213-22. PubMed ID: 25712214
[TBL] [Abstract][Full Text] [Related]
14. Lung CD103+ dendritic cells efficiently transport influenza virus to the lymph node and load viral antigen onto MHC class I for presentation to CD8 T cells.
Ho AW; Prabhu N; Betts RJ; Ge MQ; Dai X; Hutchinson PE; Lew FC; Wong KL; Hanson BJ; Macary PA; Kemeny DM
J Immunol; 2011 Dec; 187(11):6011-21. PubMed ID: 22043017
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
[TBL] [Abstract][Full Text] [Related]
16. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies.
Kim TW; Hung CF; Boyd D; Juang J; He L; Kim JW; Hardwick JM; Wu TC
J Immunol; 2003 Sep; 171(6):2970-6. PubMed ID: 12960321
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.
Dionisi M; De Archangelis C; Battisti F; Rahimi Koshkaki H; Belleudi F; Zizzari IG; Ruscito I; Albano C; Di Filippo A; Torrisi MR; Benedetti Panici P; Napoletano C; Nuti M; Rughetti A
Front Immunol; 2018; 9():2481. PubMed ID: 30455687
[TBL] [Abstract][Full Text] [Related]
18. The acquisition of antigen cross-presentation function by newly formed dendritic cells.
Sathe P; Pooley J; Vremec D; Mintern J; Jin JO; Wu L; Kwak JY; Villadangos JA; Shortman K
J Immunol; 2011 May; 186(9):5184-92. PubMed ID: 21422244
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
20. Active dissemination of cellular antigens by DCs facilitates CD8
Gurevich I; Feferman T; Milo I; Tal O; Golani O; Drexler I; Shakhar G
Eur J Immunol; 2017 Oct; 47(10):1802-1818. PubMed ID: 28872666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
